2014
Clinical cancer research: the past, present and the future
DeVita VT, Eggermont AM, Hellman S, Kerr DJ. Clinical cancer research: the past, present and the future. Nature Reviews Clinical Oncology 2014, 11: 663-669. PMID: 25245981, DOI: 10.1038/nrclinonc.2014.153.Peer-Reviewed Original Research
1997
Late sequelae of treatment of Hodgkin's disease
DeVita V. Late sequelae of treatment of Hodgkin's disease. Current Opinion In Oncology 1997, 9: 428-431. PMID: 9327220, DOI: 10.1097/00001622-199709050-00006.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseEarly-stage Hodgkin's diseaseLow-dose radiotherapyStage Hodgkin's diseaseRadiation treatment fieldLate sequelaeSecond malignanciesCombination chemotherapySuccessful treatmentClinical trialsFull dosesBreast cancerLeukemia riskSolid tumorsLow dosesYoung womenDiseaseChemotherapyTreatmentDosesTreatment fieldEarlier reportsRiskYearsReport
1985
The current status of NCI trials in Hodgkin’s disease
Young R, Longo D, Glatstein E, Duffey P, Winkler C, Wiernik P, Devita V. The current status of NCI trials in Hodgkin’s disease. Developments In Oncology 1985, 293-298. DOI: 10.1007/978-1-4613-2607-6_30.Peer-Reviewed Original Research
1982
Histologic Progression in Non-Hodgkin’s Lymphoma
Hubbard S, Chabner B, DeVita V, Simon R, Berard C, Jones R, Garvin A, Canellos G, Osborne C, Young R. Histologic Progression in Non-Hodgkin’s Lymphoma. Blood 1982, 59: 258-264. DOI: 10.1182/blood.v59.2.258.258.Peer-Reviewed Original ResearchNodular lymphomaHistological progressionLymphoma patientsHistiocytic cell typesProlonged disease-free survivalNon-Hodgkin's lymphoma patientsAssociated with prolonged survivalCell typesIntensive combination chemotherapyNon-Hodgkin's lymphomaDisease-free survivalResponse to chemotherapyNon-HodgkinCombination chemotherapyDiffuse histologyIntensive chemotherapyClinical courseBiopsy specimensProlonged survivalWorsened prognosisLymphomaNodular patternBiopsyClinical trialsDrug treatment
1981
Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.
Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981, 58: 45-51. PMID: 7236892, DOI: 10.1182/blood.v58.1.45.bloodjournal58145.Peer-Reviewed Original ResearchConceptsLong-term survivalHuge abdominal massGastrointestinal involvementAbdominal massCurrent therapiesExcellent long-term survivalBone marrow statusBone marrow involvementSubset of patientsCases of diffuseMarrow statusConstitutional symptomsMarrow involvementMedian survivalHepatic involvementPrognostic factorsClinical factorsUndifferentiated lymphomaMale sexPatient survivalSerum LDHHistopathologic materialPatient groupPoor prognosisClinical trialsMultimodal treatment of primary breast carcinoma Analysis of accomplishments and problem areas
Weiss R, Henney J, DeVita V. Multimodal treatment of primary breast carcinoma Analysis of accomplishments and problem areas. The American Journal Of Medicine 1981, 70: 844-851. PMID: 7011024, DOI: 10.1016/0002-9343(81)90541-6.Peer-Reviewed Original ResearchConceptsAxillary nodesInvolved axillary nodesDisease-free survivalUse of chemotherapyBreast carcinoma patientsCertain patient groupsFuture clinical trialsPrimary breast carcinomaBetter therapeutic indexMurine tumor modelsCarcinoma patientsDrug regimensMultimodal treatmentPatient groupClinical trialsBreast carcinomaBreast cancerTherapeutic indexChemotherapy modePatientsSpecific subgroupsTumor modelMastectomyChemotherapyHuman subjectsCurrent results of the screening program at the division of cancer treatment, national cancer institute
Goldin A, Venditti J, Macdonald J, Muggia F, Henney J, Devita V. Current results of the screening program at the division of cancer treatment, national cancer institute. European Journal Of Cancer 1981, 17: 129-142. PMID: 6894902, DOI: 10.1016/0014-2964(81)90027-x.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteScreening programCancer treatmentClinical trialsCancer InstituteHuman tumorsProspective screening programInadequate clinical trialsCategories of drugsActivity of drugsRenal capsuleClinical testingPanel testingScreening panelNew synthetic compoundsClinical interestNew drugsDrugsSubcutaneous modelTreatmentTumorsAntitumor agentsTrialsPotential usefulnessDefinitive answerAnimal toxicology for early clinical trials with anticancer agents.
Rozencweig M, Von Hoff D, Staquet M, Schein P, Penta J, Goldin A, Muggia F, Freireich E, DeVita V. Animal toxicology for early clinical trials with anticancer agents. American Journal Of Clinical Oncology 1981, 4: 21-8. PMID: 6783332.Peer-Reviewed Original ResearchConceptsPhase I clinical trialEarly clinical trialsClinical trialsOrgan system toxicityStarting doseSystem toxicityChemotherapeutic agentsDose-escalation stepsCommon toxic effectsGastrointestinal intoleranceInitial doseClinical dataEscalation stepsAnimal findingsToxic doseToxic manifestationsIndividual drugsPredictive valueAnimal toxicologyMiceDoseIdentical scheduleLD10Acceptable dosesDogs
1980
The evolution of primary multimodality treatment in resectable breast cancer
Henney J, Devita V. The evolution of primary multimodality treatment in resectable breast cancer. Cancer 1980, 46: 999-1008. PMID: 6994877, DOI: 10.1002/1097-0142(19800815)46:4+<999::aid-cncr2820461325>3.0.co;2-e.Peer-Reviewed Original ResearchConceptsDisease-free intervalPremenopausal womenClinical trialsBreast cancerProspective randomized clinical trialsStage II breast cancerAdjuvant therapy studiesResectable breast cancerRandomized clinical trialsNational Cancer InstitutePositive resultsPostmenopausal womenMultimodality treatmentPostoperative periodPrognostic factorsNational mortalityClinical dataEstrogen receptorDrug doseCancer InstituteStage IClinical researchPatientsTherapy studiesTrials
1979
Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
Weiss R, DeVita V. Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. Annals Of Internal Medicine 1979, 91: 251-60. PMID: 380437, DOI: 10.7326/0003-4819-91-2-251.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrimary treatment programGroup of patientsAdvanced diseaseTherapy regimensPrimary lesionSurgical removalAdult malignanciesPalliative treatmentTreatment resultsClinical trialsHuman trialsCancer mortalityChemotherapyMalignancyTreatment programsTreatmentRegimensPatientsLesionsCancerAdvanced Ovarian Adenocarcinoma A Prospective Clinical Trial of Melphalan (L-PAM) Versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, Devita V. Advanced Ovarian Adenocarcinoma A Prospective Clinical Trial of Melphalan (L-PAM) Versus Combination Chemotherapy. Obstetrical & Gynecological Survey 1979, 34: 414. DOI: 10.1097/00006254-197905000-00027.Peer-Reviewed Original Research
1978
Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, DeVita V. Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy. New England Journal Of Medicine 1978, 299: 1261-1266. PMID: 101843, DOI: 10.1056/nejm197812072992301.Peer-Reviewed Original ResearchConceptsAdvanced ovarian adenocarcinomaFour-drug combinationOverall response rateOvarian adenocarcinomaComplete remissionMedian survivalResidual diseaseResponse rateHigher overall response rateExtensive residual diseaseFour-drug regimenProspective clinical trialsLonger median survivalMinimal residual diseaseAdvanced diseaseCombination chemotherapyClinical trialsSevere toxicityMelphalanPatientsAdenocarcinomaDiseaseRemissionTrialsSurvivalHigh volume intraperitoneal chemotherapy (“Belly bath”) for ovarian cancer
Jones R, Myers C, Guarino A, Dedrick R, Hubbard S, DeVita V. High volume intraperitoneal chemotherapy (“Belly bath”) for ovarian cancer. Cancer Chemotherapy And Pharmacology 1978, 1: 161-166. PMID: 373916, DOI: 10.1007/bf00253116.Peer-Reviewed Original ResearchConceptsOvarian cancerIntraperitoneal chemotherapyPhase I clinical trialAdvanced stage diseaseIntraperitoneal fluid volumeIntraperitoneal methotrexateComplete remissionTreatment modalitiesPharmacologic principlesClinical trialsPeritoneal cavityTherapeutic effectivenessChemotherapyPharmacokinetic modelingDialysis fluidToxicologic studiesCancerFluid volumeDrug distributionRational chemotherapyFurther investigationRemissionPatientsMethotrexatePharmacokinetics
1976
Combined modality treatment of American Burkittapos;s lymphoma
Ziegler J, Devita V, Graw R, Herzig G, Leventhal B, Levine A, Pomeroy T. Combined modality treatment of American Burkittapos;s lymphoma. Cancer 1976, 38: 2225-2231. PMID: 1036716, DOI: 10.1002/1097-0142(197612)38:6<2225::aid-cncr2820380606>3.0.co;2-f.Peer-Reviewed Original ResearchConceptsBurkitt's lymphomaCombined modality treatmentBone marrow autograftsMajor therapeutic goalPrevention of relapseThird remissionFirst remissionIntensive chemotherapyComplete responseModality treatmentInitial treatmentAmerican patientsMarrow autograftsRisk factorsClinical trialsTherapeutic goalsPatientsLymphomaRemissionChemotherapyTreatmentImmunotherapyRelapseRadiotherapyAutograftTreatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine.
Young R, DeVita V. Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine. National Cancer Institute Monograph 1976, 43: 193-200. PMID: 1087955.Peer-Reviewed Original ResearchConceptsPyrimethamine-sulfadiazinePneumocystis pneumoniaPentamidine isethionateClinical trialsPneumocystis carinii pneumoniaManagement of patientsSeverely ill patientsRandomized clinical trialsCarinii pneumoniaLocal toxicityRegimensIll patientsPatientsComplete recoveryPneumoniaPneumocystisIsethionateComparative toxicityTrialsPentamidineToxicityPerspectives on research in gynecologic oncology. Treatment protocols
Devita V, Wasserman T, Young R, Carter S. Perspectives on research in gynecologic oncology. Treatment protocols. Cancer 1976, 38: 509-525. PMID: 776390, DOI: 10.1002/1097-0142(197607)38:1<509::aid-cncr2820380175>3.0.co;2-a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAlkylating AgentsAntineoplastic AgentsCarcinoma, Squamous CellClinical Trials as TopicDrug EvaluationDrug Therapy, CombinationFemaleGenital Neoplasms, FemaleHumansHysterectomyMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsProgestinsUterine Cervical NeoplasmsUterine NeoplasmsConceptsClinical trialsOvarian cancerAdvanced uterine cancerPostoperative adjuvant chemotherapyStage II diseaseMetastatic cervical cancerEffective adjuvant treatmentEffect of radiotherapyUse of adriamycinUse of hydroxyureaCombination of drugsL-phenylalanine mustardPathways of spreadMore effective drugsAdjuvant chemotherapyInoperable diseaseResectable tumorsAdjuvant treatmentAdvanced diseasePostoperative radiotherapySystemic chemotherapyGynecologic malignanciesSystemic treatmentTreatment failureUterine cervix
1975
Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy.
Canellos G, DeVita V, Young R, Chabner B, Schein P, Johnson R. Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy. British Journal Of Cancer. Supplement 1975, 2: 474-80. PMID: 1101933, PMCID: PMC2149565.Peer-Reviewed Original ResearchCombination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer
Devita V, Young R, Canellos G. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 1975, 35: 98-110. PMID: 162854, DOI: 10.1002/1097-0142(197501)35:1<98::aid-cncr2820350115>3.0.co;2-b.Peer-Reviewed Original ResearchMeSH KeywordsAdenoma, Islet CellAlkylating AgentsAntineoplastic AgentsBinding, CompetitiveBreast NeoplasmsBurkitt LymphomaChoriocarcinomaCyclophosphamideDrug ResistanceDrug Therapy, CombinationFemaleHodgkin DiseaseHumansLeukemia, LymphoidNeoplasm MetastasisNeoplasmsOvarian NeoplasmsPancreatic NeoplasmsPregnancy
1974
The design of clinical trials in the therapy of ovarian carcinoma
Young R, DeVita V. The design of clinical trials in the therapy of ovarian carcinoma. American Journal Of Obstetrics And Gynecology 1974, 120: 1012-1024. PMID: 4432892, DOI: 10.1016/0002-9378(74)90143-4.Peer-Reviewed Original ResearchConceptsOvarian carcinomaClinical trialsProspective randomized clinical trialsSurvival of patientsCombined modality approachRandomized clinical trialsPrognostic factorsStandardized stagingModality approachTherapySuch trialsCarcinomaMajor causeTrialsPatientsBase lineSurvivalChemotherapyRadiotherapyStagingWomen
1973
Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man
Sponzo R, Devita V, Oliverio V. Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man. Cancer 1973, 31: 1154-1159. PMID: 4705152, DOI: 10.1002/1097-0142(197305)31:5<1154::aid-cncr2820310517>3.0.co;2-b.Peer-Reviewed Original Research